Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

2019260 citationsJournal Articlegold Open Access

Authors

NCTN, NCT02536469. Registered 23 August 2015, https://clinicaltrials.gov/ct2/show/NCT02536469?term=NCT02536469&rank=1 .

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 7, Issue 1, pp. 240-240

Field-Weighted Citation Impact: 12.51